PT  - JOURNAL ARTICLE
AU  - Karim, F
AU  - Moosa, MYS
AU  - Gosnell, BI
AU  - Cele, S
AU  - Giandhari, J
AU  - Pillay, S
AU  - Tegally, H
AU  - Wilkinson, E
AU  - San, JE
AU  - Msomi, N
AU  - Mlisana, K
AU  - Khan, K
AU  - Bernstein, M
AU  - Manickchund, N
AU  - Singh, L
AU  - Ramphal, U
AU  - ,
AU  - Hanekom, W
AU  - Lessells, RJ
AU  - Sigal, A
AU  - de Oliveira, T
TI  - Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infection
AID  - 10.1101/2021.06.03.21258228
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.03.21258228
4099  - http://medrxiv.org/content/early/2021/06/04/2021.06.03.21258228.short
4100  - http://medrxiv.org/content/early/2021/06/04/2021.06.03.21258228.full
AB  - While most people effectively clear SARS-CoV-2, there are several reports of prolonged infection in immunosuppressed individuals. Here we present a case of prolonged infection of greater than 6 months with shedding of high titter SARS-CoV-2 in an individual with advanced HIV and antiretroviral treatment failure. Through whole genome sequencing at multiple time-points, we demonstrate the early emergence of the E484K substitution associated with escape from neutralizing antibodies, followed by other escape mutations and the N501Y substitution found in most variants of concern. This provides support to the hypothesis of intra-host evolution as one mechanism for the emergence of SARS-CoV-2 variants with immune evasion properties.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSouth African Medical Research Council (SAMRC), Department of Science and Innovation (DSI) of South Africa and the Bill and Melinda Gates Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol for the prospective cohort study exploring the effect of HIV and TB on the natural history and immune response to SARS-CoV-2 infection was approved by the Biomedical Research Ethics Committee of the University of KwaZulu-Natal (ref. BREC/00001275/2020) and the KwaZulu-Natal Provincial Health Research and Ethics Committee (ref. KZ_202005_003). We obtained written informed consent from all participants. Additionally, we obtained written informed consent for publication from the participant described in this report.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll of the genomes are available at GISAID and short-read data at the Short Read Archive (SRA) of NCBI/EBI